Analyst Price Targets — VIR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 11:41 am | Patrick Trucchio | H.C. Wainwright | $20.00 | $9.13 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright |
| February 26, 2026 6:07 pm | Roanna Ruiz | Leerink Partners | $20.00 | $9.33 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $20 at Leerink Partners |
| February 24, 2026 7:22 pm | — | Barclays | $30.00 | $9.49 | TheFly | Vir Biotechnology price target raised to $30 from $26 at Barclays |
| February 24, 2026 1:02 pm | Cory Kasimov | Evercore ISI | $18.00 | $9.70 | TheFly | Vir Biotechnology price target raised to $18 from $12 at Evercore ISI |
| February 24, 2026 12:05 pm | Joseph Stringer | Needham | $18.00 | $9.64 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $18 at Needham |
| February 24, 2026 11:49 am | Michael Ulz | Morgan Stanley | $24.00 | $7.43 | TheFly | Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley |
| February 24, 2026 11:05 am | Sean McCutcheon | Raymond James | $19.00 | $9.69 | StreetInsider | Raymond James Upgrades Vir Biotechnology (VIR) to Strong Buy |
| February 17, 2026 11:36 am | — | Barclays | $26.00 | $7.47 | TheFly | Vir Biotechnology price target raised to $26 from $24 at Barclays |
| February 4, 2026 10:46 am | Etzer Darout | Barclays | $24.00 | $7.68 | TheFly | Vir Biotechnology price target lowered to $24 from $31 at Barclays |
| December 30, 2025 11:38 am | Patrick Trucchio | H.C. Wainwright | $15.00 | $5.98 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Vir Biotechnology (VIR) |
Latest News for VIR
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its global collaboration and licensing agreement with Astellas announced on February 23, 2026 has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The collaboration aims to accelerate the development of VIR-5500, a prostate-specific membrane antigen…
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) for metastatic prostate cancer (NCT05997615). The Phase 1 trial is measuring the safety and efficacy of VIR-5500…
72,559 shares were sold for a total transaction value of ~$664,000 on April 6, 2026. This sale represented 6.76% of De Backer's total holdings at the time of the transaction.
Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) CEO Backer Marianne De sold 72,559 shares of the firm's stock in a transaction on Monday, April 6th. The stock was sold at an average price of $9.16, for a total value of $664,640.44. Following the completion of the transaction, the chief executive officer owned 948,145 shares
Citigroup Inc. reduced its position in Vir Biotechnology, Inc. (NASDAQ: VIR) by 22.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 323,525 shares of the company's stock after selling 92,426 shares during the quarter. Citigroup Inc. owned
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VIR.
U.S. House Trading
No House trades found for VIR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.